3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Status
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
3
Genitourinary
2
Thoracic
1
Lymphoid
1
Conditions
Prostatic Neoplasms
2
Motor Activity
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
182
Magnetic Resonance Spectroscopy
161
Specimen Handling
134
enzalutamide
125
Nivolumab
118
Gemcitabine
99
Docetaxel
93
Radiosurgery
91
Prednisone
83
Androgen Antagonists
81
Abiraterone Acetate
81
Radiotherapy
75
apalutamide
67
Cisplatin
65
darolutamide
62
Ipilimumab
61
Biopsy
61
abiraterone
57
cabozantinib
55
Carboplatin
55
Leuprolide
53
enfortumab vedotin
50
Radiation
47
Pluvicto
45
Standard of Care
44
atezolizumab
41
Surveys and Questionnaires
38
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
37
X-Rays
37
avelumab
35
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
High-Intensity Interval Training
×
Genitourinary
×
1 year
×
Clear all
NCT04558398
2026-04-29
ICCE-Mito
University of Nottingham
Phase NA
Completed
15 enrolled
NCT07518888
2026-04-09
ESCAPE
University of Miami
Phase NA
Not yet recruiting
49 enrolled